This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes in Stage III (cTNM-IIIB/IIIC) Non-Small Cell Lung Cancer.Patients meeting inclusion and exclusion criteria were enrolled, with treatment modalities and clinical outcomes of stage III non-small cell lung cancer (NSCLC) patients from multiple tertiary hospitals in real-world settings since August 2020 being collected and analyzed.
Key Inclusion Population： Stage IIIB/IIIC NSCLC patients confirmed by histological or cytological examination based on the 8th edition of the AJCC staging system.Patients were negative for EGFR-sensitive mutations or ALK/ROS1 fusion alterations. No prior chemotherapy, radiotherapy, surgical intervention, or immunotherapy had been administered.ECOG PS scores of the enrolled patients ranged from 0 to 2. Neoadjuvant/Induction Therapy Regimen: Tislelizumab combined with platinum-based doublet chemotherapy was administered for at Least Two Cycles , followed by surgical resection or other therapeutic interventions (e.g., radiotherapy/chemotherapy). Real-world clinical outcomes were collected and analyzed based on patients' subsequent treatment pathways.Clinical Stage IIIB-IIIC Non-Small Cell Lung Cancer (AJCC 8th Edition Staging); ECOG PS Score 0-2 Retrospective data collection was conducted for cases prior to site initiation, while prospective collection was implemented for post-initiation cases. Collected parameters include: 1. Patient clinical characteristics 2. Treatment patterns 3. Treatment compliance 4. Safety profiles 5. Event-free survival (EFS) and overall survival (OS) tracking
Study Type
OBSERVATIONAL
Enrollment
200
Tislelizumab Combined with Chemotherapy as Induction Therapy
major pathological response
viable tumor cell less than 10%
Time frame: ;usually 1 week after surgery
R0 resection rate
margin negative resection
Time frame: ,usually 1 week after surgery
Down-staging rate
clinical and pathological downstaging
Time frame: usually 1 week after surgery
Impact of Neoadjuvant Therapy on Surgical Outcomes
Surgical Rate
Time frame: usually 1 week after surgery
The outcome of survival
patterns and Outcomes of Postoperative Disease Recurrence/Progression
Time frame: usually 12 month after Induction Therapy
12month event-free survival rate
the time from randomization to any progression of disease precluding surgery, progresson or recurrence of disease after surgery, progression of disease in the absence of surgery, or death from any cases;
Time frame: rom date of diagnosis until the date of first documented progression, the rate of recurrence or date of death from any cause, whichever came first, assessed up to 12 months
OS
From diagnosis to the death;
Time frame: from date of diagnosis until the date of death from any cause, whichever came first, assessed up to 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.